Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07134088) titled 'A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia' on Aug. 14.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Amgen
Condition:
Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
Intervention:
Drug: Blinatumomab
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: November 21, 2025
Target Sample S...